Good call dum-dum.
GBA Presents: House of Gummy-!
- Thread starter stonedinvestor
- Start date
I'll try and get this report- Not much of a price raise but at least not a reduce.
Fluence Energy price target raised to $35 from $34 at Goldman Sachs » 19:40 FLNC
Fluence Energy price target raised to $35 from $34 at Goldman Sachs » 19:40 FLNC
Evolv Technology raises FY23 revenue view to $70M-$75M from $60M-$65M » 16:21 EVLV Consensus $64.94M. Raises…
Carrols Restaurant price target raised to $10 from $6 at Stephens » 16:14 TAST
Amylyx reports Q2 EPS 31c, consensus 10c » 16:02 AMLX--
TOMORROW'S GUMMY TODAY-!
Amylyx Pharmaceuticals, Inc. (AMLX)
NasdaqGS - NasdaqGS Real Time Price
21.17-0.32(-1.49%)
At close: 04:00PM EDT
21.43+0.26(+1.23%)<------ SHOULD BE MORE!!!!
After hours:07:55PM EDT
TOMORROW'S GUMMY TODAY-!
Amylyx Pharmaceuticals, Inc. (AMLX)
NasdaqGS - NasdaqGS Real Time Price
21.17-0.32(-1.49%)
At close: 04:00PM EDT
21.43+0.26(+1.23%)<------ SHOULD BE MORE!!!!
After hours:07:55PM EDT
Cambridge Mass Co-
Description
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Description
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
I mean-- This is a huge beat-
Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.93 per share a year ago. These figures are adjusted for non-recurring items.
Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.93 per share a year ago. These figures are adjusted for non-recurring items.
WE GOT TO BUY AMLX TOMM--
$24.69 <--- This stk (AMLX) was here when they apparently did not do well last qtr March 31//
Now they score huge can we not start at the old spot $24 and go up from there?
This seems like an opportunity.
Now they score huge can we not start at the old spot $24 and go up from there?
This seems like an opportunity.
Stoney why not BLDR?